Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.

SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (DMD)

• SGT-003 continues to be well tolerated in the first four patients dosed in the ongoing INSPIRE DUCHENNE clinical trial.
• Patient enrollment and dosing under the expanded INSPIRE DUCHENNE protocol is ongoing.
• Six clinical sites are activated in North America (five in the U.S., one in Canada).
• The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) cleared the INSPIRE DUCHENNE clinical trial application (CTA) with initial site activation expected in 2H 2025.
• Solid expects to report data from the first three patients dosed in Q1 2025.

Learn More: Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy